{
    "nct_id": "NCT04670445",
    "official_title": "Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer",
    "inclusion_criteria": "* All participants (Patients and Caregivers)-Table 1\n\n  * Age 18 or older\n  * Ability to read and respond in English\n* Patient Inclusion Criteria (in addition to Table 1)\n\n  * Receiving care in the MGH Cancer Center\n  * Diagnosis of advanced (stage IV) melanoma or advanced, incurable lung cancer, including stage IV non-small cell lung cancer (NSCLC), unresectable stage III NSCLC, extensive-stage small cell lung cancer.\n  * Plan to initiate immunotherapy with an ICI (pembrolizumab, nivolumab, ipilimumab, atezolizumab or combination), per clinician documentation in the electronic health record or study staff communication with clinician\n* Caregiver Inclusion Criteria (in addition to Table 1)\n\n  * Identified as \"a supportive person involved in their cancer care\" by a patient enrolled in the study\n\nExclusion criteria\n\n* Major psychiatric condition or comorbid illness that prohibits participation in the study\n* Cognitive impairment that prohibits provision of informed consent or participation in the study\n* Pregnant women\n* Prisoners\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}